Mirae Asset Global Etfs Holdings Ltd. Arcus Biosciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 37,572 shares of RCUS stock, worth $335,517. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,572
Previous 34,007
10.48%
Holding current value
$335,517
Previous $506,000
41.9%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RCUS
# of Institutions
200Shares Held
63.1MCall Options Held
116KPut Options Held
116K-
Black Rock Inc. New York, NY9.76MShares$87.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$59.7 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$45.8 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$33 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$25.6 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $644M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...